SmartPeptide
Start Free
MuscleLimited human evidence

GHRP-2

Growth Hormone Releasing Peptide-2. Synthetic hexapeptide ghrelin-receptor agonist. Stimulates GH release potently and consistently. Studied since the 1990s; approved in some Asian markets for diagnostic GH stimulation, NOT for therapeutic use in the US.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Strong, reproducible GH release in healthy adults; used diagnostically in some countries to assess GH reserve. Body-composition / athletic performance benefits in humans are not established in modern RCTs.

What's still experimental

Therapeutic adult use, long-term safety, optimal cycling, combinations with CJC-1295 etc.

Anecdotal / community reports

Heavy bodybuilding-community use. Reports of recovery / sleep / appetite changes are anecdotal and confounded.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “GHRP-2”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

Source: Published clinical trial

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

Community-anecdotal range — NOT a SmartPeptide recommendation

The doses below are aggregated from research-peptide community forums (Reddit, biohacker discussions). They are NOT supported by clinical trials, NOT FDA-approved, and NOT a SmartPeptide recommendation. Source purity, dose accuracy, and user-reported outcomes are unverifiable. We display this only because the information is publicly available elsewhere — visitors should absolutely consult a licensed clinician familiar with experimental peptides before any use.

Community-anecdotal — not evidence-basedBodybuilding + performance community forums
Indication studied: Community-discussed for GH stimulation (approved diagnostically in some Asian markets, not US-therapeutic)
Typical
100µg
1-3x daily · subcutaneous

Most-discussed range

Open calculator
Maximum
300µg
1-3x daily · subcutaneous

Higher community range

Open calculator

Notes from the source: Notable for pronounced appetite stimulation (hunger). Hyperprolactinemia and cortisol elevation are documented effects.

Important framing: The numbers above are what published trials tested or what FDA-approved labels specify. They are NOT a SmartPeptide recommendation for you. Trial doses come paired with screening, monitoring, and clinician oversight. Always consult a licensed clinician before any peptide use.

How clinicians typically protocol this

Third-party reference · not our recommendation

Dosing phases, cycle lengths, and administration timing as listed in a compounding-pharmacy clinician reference guide. Shown so you can see what a real protocol looks like — and bring informed questions to a licensed clinician.

Third-party protocol referenceCompounding-pharmacy clinician protocol reference (Nov 2025)

Dose numbers, frequencies, and cycle lengths in this panel are extracted from a clinician-facing reference protocol distributed by a US-based compounding pharmacy in November 2025. SmartPeptide has paraphrased all descriptive text and adds no endorsement. Always consult a licensed clinician.

Growth Hormone

GHRP / ghrelin-mimetic hexapeptide; a GH secretagogue.

Protocol phases

Typical
200–500 µg5 days/week AM
subcutaneous

pre-workout, fasted

Cycle length

12–14 weeks on / 4–8 weeks off. Higher doses split 2–3× daily.

Administration timing

Often paired with CJC-1295. Carbs and fat blunt GH release.

Reported side effects
Increased hungerWater retentionExtremity tingling

Protocol notes: The reference notes this compound is often chosen during bulking phases or for appetite loss due to illness.

Reconstitution calculator Storage & reconstitution guide
Not medical advice. SmartPeptide does not prescribe, diagnose, or treat. The protocol above reproduces dose figures from a third-party clinician reference so you can see what compounding-pharmacy guidance typically looks like — it is not a recommendation for you, and it has not been validated against peer-reviewed dose-ranging trials. Many of these compounds are not FDA-approved for human use. Work with a licensed clinician familiar with peptide therapy before considering anything here.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
Total actions
29
recalls + withdrawals
Ongoing
3
not yet completed
Class I (serious)
0
health hazard / death risk
  • Class IITerminated· Voluntary: Firm initiated
    FDA record

    Sermorelin, 3 mg / GHRP-2, 3 mg / Vial, For SC Use-Lyophilized, Rx Only, KRS Global Biotechnology 791 Park of Commerce Blvd, Boca Raton, FL 33487. NDC 3321674092

    Reason: Lack of Assurance of Sterility

    Sep 12, 2019·KRS Global Biotechnology, Inc
  • Class IITerminated· Voluntary: Firm initiated
    FDA record

    Sermorelin Acetate, 9 mg / GHRP-2, 5.4 mg/vial Lyophilized-for SC Use, Rx Only, KRS Global Biotechnology 791 Park of Commerce Blvd, Boca Raton, FL 33487. NDC 3321674047

    Reason: Lack of Assurance of Sterility

    Sep 12, 2019·KRS Global Biotechnology, Inc
  • Class IITerminated· FDA Mandated
    FDA record

    Sermorelin/GHRP-2 9 mg/6 mg vials, Rx only, Pharm D. Solutions 1304 South Loop West, Houston, TX 77054, 1-844-263-6846

    Reason: Lack of Sterility Assurance.

    May 23, 2019·Pharm D Solutions, LLC
  • Class IITerminated· FDA Mandated
    FDA record

    Sermorelin/GHRP-2 &6 (9-9-9-mg) vials, Pharm D. Solutions 1304 South Loop West, Houston, TX 77054, 1-844-263-6846

    Reason: Lack of Sterility Assurance.

    May 23, 2019·Pharm D Solutions, LLC
  • Class IITerminated· FDA Mandated
    FDA record

    Sermorelin/GHRP-2 &6 (9-9-9 mg) vials, Pharm D. Solutions 1304 South Loop West, Houston, TX 77054, 1-844-263-6846

    Reason: Lack of Sterility Assurance.

    May 23, 2019·Pharm D Solutions, LLC
Showing 8 of 29 total enforcement actions. See full FDA history →
FDA classifications: Class I = reasonable probability of serious adverse health consequences or death. Class II = temporary or medically reversible adverse consequences. Class III = unlikely to cause adverse health consequences.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Formula
C45H55N9O6

Protein targets (UniProt)

  • Growth hormone secretagogue receptor type 1
    Q92847gene: GHSRHomo sapiens· 366 aaReviewed

    G protein-coupled receptor specific to ghrelin, an appetite-regulating peptide hormone commonly found in stomach (PubMed:35027551, PubMed:39833471). Upon activation, stimulates appetite and promotes growth hormone secretion (PubMed:10604470, PubMed:11322507, PubMed:35027551, PubMed:39833471). Ghrelin binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as phospholipase C (By simi…

  • Growth hormone secretagogue receptor type 1
    A5A4K9gene: GHSROryctolagus cuniculus· 366 aaReviewed

    G protein-coupled receptor specific to ghrelin, an appetite-regulating peptide hormone commonly found in stomach. Upon activation, stimulates appetite and promotes growth hormone secretion (By similarity). Ghrelin binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as phospholipase C. GHSR is coupled to G(q) G proteins and mediates production of diacylglycerol (DAG) and inositol…

  • Growth hormone secretagogue receptor type 1
    Q95254gene: GHSRSus scrofa· 366 aaReviewed

    G protein-coupled receptor specific to ghrelin, an appetite-regulating peptide hormone commonly found in stomach. Upon activation, stimulates appetite and promotes growth hormone secretion (By similarity). Ghrelin binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as phospholipase C. GHSR is coupled to G(q) G proteins and mediates production of diacylglycerol (DAG) and inositol…

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
256
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
0 total registered

Europe PMC — 2,064 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
3,124
all years
Last 5 years
821
recent activity
Open access
2,558
freely readable
OA share
82%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “GHRP-2 OR pralmorelin” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
271
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • University of Isfahan2 works
  • University of Cádiz2 works
  • National Natural Science Foundation of China2 works
  • National Key Research and Development Program of China2 works
  • National Institute on Alcohol Abuse and Alcoholism2 works
  • Albert Szent-Györgyi School of Medicine, University of Szeged, Hungary1 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 8 preprints indexed by Europe PMC.

Known risks

Hyperprolactinemia, cortisol elevation, appetite stimulation (notable). Long-term safety in non-diagnostic use is unestablished. Source quality varies dramatically.

Reported side effects

Hunger (often pronounced), injection-site reactions, mild flushing, possible nausea, water retention.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
Reports filed
4
FAERS, all years
Serious reports
3
75% of reports
Top reporting countries
  • US4

Most-reported reactions

  • Urticaria
    2
  • Abdominal Pain Upper
    1
  • Burning Sensation
    1
  • Injection Site Urticaria
    1
  • Nausea
    1
  • Pain
    1
  • Pancreatitis Acute
    1
  • Product Lot Number Issue
    1
  • Product Physical Consistency Issue
    1
  • Product Quality Issue
    1

Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs

What requires medical supervision

Not FDA-approved for therapeutic use in the US. Discuss with a clinician familiar with experimental peptides before any use.

Questions for your clinician

  • Why GHRP-2 vs FDA-approved sermorelin/tesamorelin?
  • What labs would we track?
  • What's our stop criteria?

Editorially curated references

Discussions about GHRP-2

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all GHRP-2 discussions Native, moderated, no buying or selling